Search research articles
Contact Us
Filters
Showing results (1131-1140 of 1,216) with videos related to
Page
of 122
Sort By:
Neuro-Oncology
|
November 13, 2018
Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool
Paul W Sperduto, Brian J Deegan, Jing Li, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2018
Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases
Paul W Sperduto, Brian J Deegan, Jing Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2026
Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma
Rupesh Kotecha, Mei-Yin Polley, Michael A Vogelbaum, et al.
Journal of Neuro-Oncology
|
November 11, 2021
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825
Nirav Patil, Eashwar Somasundaram, Kristin A Waite, et al.
Neuro-Oncology
|
January 14, 2025
Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial Design
Rupesh Kotecha, Eyub Y Akdemir, Tugce Kutuk, et al.
Journal of Neuro-Oncology
|
August 29, 2019
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, et al.
Journal of Medicinal Chemistry
|
August 24, 2010
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease
Daniel P Becker, Thomas E Barta, Louis J Bedell, et al.
Blood
|
July 20, 2006
Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients
Katrin Tefs, Maria Gueorguieva, Jürgen Klammt, et al.
Cancer Discovery
|
November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway
Deliang Guo, Felicia Reinitz, Mary Youssef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2020
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Paul D Brown, Vinai Gondi, Stephanie Pugh, et al.
Page
of 122
Search research articles
Search
Showing results (1131-1140 of 1,216) with videos related to
Sort By:
Page
of 122
Neuro-Oncology
|
November 13, 2018
Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool
Paul W Sperduto, Brian J Deegan, Jing Li, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2018
Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases
Paul W Sperduto, Brian J Deegan, Jing Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2026
Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma
Rupesh Kotecha, Mei-Yin Polley, Michael A Vogelbaum, et al.
Journal of Neuro-Oncology
|
November 11, 2021
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825
Nirav Patil, Eashwar Somasundaram, Kristin A Waite, et al.
Neuro-Oncology
|
January 14, 2025
Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial Design
Rupesh Kotecha, Eyub Y Akdemir, Tugce Kutuk, et al.
Journal of Neuro-Oncology
|
August 29, 2019
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, et al.
Journal of Medicinal Chemistry
|
August 24, 2010
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease
Daniel P Becker, Thomas E Barta, Louis J Bedell, et al.
Blood
|
July 20, 2006
Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients
Katrin Tefs, Maria Gueorguieva, Jürgen Klammt, et al.
Cancer Discovery
|
November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway
Deliang Guo, Felicia Reinitz, Mary Youssef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2020
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Paul D Brown, Vinai Gondi, Stephanie Pugh, et al.
Page
of 122